Guam Disease

Guam disease is a rare brain and nerve disorder that was once common in the Indigenous Chamorro people of Guam and in a few other Western Pacific locations. Doctors now call it amyotrophic lateral sclerosis–parkinsonism–dementia complex (ALS/PDC). The name tells you what it looks like: some people show signs like ALS (weak, thinning muscles and trouble speaking or swallowing), some show parkinsonism (slowness, stiffness, balance problems), and some develop dementia (thinking and memory problems). Many people have a mixed picture over time. Under the microscope, the disease shows abnormal build-up of proteins (notably tau, and sometimes Aβ and TDP-43) in brain and spinal cord cells. The exact cause is still not proven. MedLink+2PubMed+2

“Guam disease” is the local name for a rare brain and nerve illness first seen in the Chamorro people of Guam. Doctors call it ALS–Parkinsonism–Dementia Complex (ALS-PDC), and Chamorros call it lytico-bodig. It combines three kinds of problems in one person:

• ALS-like weakness (muscles get weak and thin),

• Parkinson-like movement changes (slowness, stiffness, shaking, falls), and

• Dementia-like thinking changes (memory and behavior problems).
  Over time, the condition worsens and can lead to trouble swallowing and breathing. It is very rare now compared with the mid-1900s peak, and likely linked to environmental exposures plus personal susceptibility rather than a single gene. PubMed+2PubMed+2

Other names

People may use different names for the same condition:

• Lytico-bodig (Chamorro words: lytico ≈ the ALS-like form; bodig ≈ the parkinsonism-dementia form).

• ALS/PDC (amyotrophic lateral sclerosis/parkinsonism-dementia complex).

• Guamanian ALS or Guam ALS/PDC.

• Western Pacific ALS/PDC (also reported in the Kii Peninsula of Japan and parts of Papua). MedLink

Types

1. Lytico-predominant (ALS-like) form. The main problem is progressive weakness, muscle wasting, cramps, twitching, and later speech and swallowing trouble. Reflexes can be brisk, and walking becomes difficult. Thinking is often preserved early but may be affected later. MedLink

2. Bodig-predominant (parkinsonism-dementia) form. The main problems are slowness, stiffness, balance issues, falls, a quiet voice, and thinking changes (especially attention and planning). Eye-movement problems and a “hummingbird sign” on brain scans (similar to PSP) have been described in some cases. E-JMD

3. Mixed form. Many people shift over time, for example starting with parkinsonism and later developing weakness like ALS, or vice versa. MedLink

---

Causes and risk factors

Important note: the true cause is not proven. Several ideas exist, and some have both supporting and conflicting data. Think of these as hypotheses or risk factors, not final answers.

1. Cycad plant toxins in the diet. Seeds of local cycad plants contain toxins (including BMAA and MAM) that may harm nerve cells. Historical reliance on cycad flour—especially around World War II—raised exposure. Evidence is mixed but remains a leading theory. BioMed Central+1

2. Biomagnification through food chains. The neurotoxin BMAA may concentrate in fruit bats (flying foxes) that eat cycad seeds; eating these bats could deliver very high doses. PubMed

3. Cyanobacteria (blue-green algae) as a source of BMAA. BMAA can be produced by cyanobacteria and enter the local ecosystem and food supply. PMC

4. “Double-prion” proteinopathy hypothesis. Newer work suggests Guam ALS/PDC brains contain tau and Aβ seeds (“prions”), which might drive disease spread inside the nervous system. This explains pathology, but not the original trigger. PMC+2PubMed+2

5. TDP-43 interaction with tau. Research in neurodegeneration shows TDP-43 abnormalities can worsen tau build-up, possibly relevant to mixed protein changes in ALS/PDC. BioMed Central

6. Mineral or micronutrient imbalance. Older hypotheses proposed low calcium/magnesium or other dietary shifts as cofactors; evidence is limited and indirect. (General background in ALS-like Western Pacific reviews.) MedLink

7. Other cycad toxins (MAM/cycasin). Besides BMAA, cycad seeds contain genotoxins like methylazoxymethanol (MAM) that can damage cells and DNA in lab models. BioMed Central

8. Food processing practices. Incomplete washing/soaking of cycad flour may leave more toxin in the food. This is part of the historical exposure hypothesis. PubMed

9. Historical dietary patterns and food scarcity. Wartime/jungle subsistence likely increased reliance on cycad products and wild meat, raising toxin exposure compared with earlier or later periods. University of Guam

10. Ecologic change in key species. Declines in fruit bat populations paralleled declines in lytico-bodig incidence, consistent with reduced biomagnified toxin exposure (an ecological clue, not proof). Guampedia

11. Age. Risk rises with age, as in most neurodegenerative diseases; presentations vary from mid-life to older age. (Pattern described in reviews.) MedLink

12. Genetic susceptibility (modifiers). Population studies searched for genetic risk but have not identified a single causative gene; genes may modify risk or phenotype in the presence of environmental exposure. JAMA Network

13. Oxidative stress/excitotoxicity pathways. Proposed mechanisms by which BMAA and related toxins may injure neurons in models; human proof remains incomplete. PMC

14. Mitochondrial dysfunction. Suggested mechanism in many neurodegenerative diseases; may be a downstream effect rather than the primary cause here. (General mechanistic context.) MedLink

15. Protein misfolding cascade. The presence of tau/Aβ “prion-like” seeds suggests a spread of misfolded proteins once initiated. PMC

16. Regional clustering (Western Pacific). The tight geographic clustering argues for shared environment and culture more than a widespread hereditary disease. MedLink

17. Declining incidence over decades. Rates fell markedly from mid-20th century to recent times, consistent with changing exposures; exact reasons remain unclear. Oxford Academic+1

18. Possible cumulative lifetime exposure. Long-term, low-level toxin exposure (instead of one big dose) is another suggested pattern. Evidence remains indirect. PMC

19. Co-exposure to multiple agents. Some scientists argue BMAA alone may not explain everything; combinations of toxins or other cofactors may be needed. The Lancet

20. Unidentified triggers. A fair position in recent scholarship is that the etiology is still unresolved, even as pathology is better defined. PMC

---

Common symptoms and signs

1. Muscle weakness. Arms and legs get weak. Tasks like climbing stairs, lifting objects, or opening jars become hard. In the lytico form, weakness slowly spreads.

2. Muscle wasting (thinning). Muscles shrink over time because nerves that control them are sick.

3. Twitching and cramps. Small muscle jerks (fasciculations) and painful cramps can occur, especially in hands, arms, and legs.

4. Spasticity and brisk reflexes. Stiff muscles, tightness, and jumpy reflexes show upper-motor-neuron involvement.

5. Speech problems. The voice becomes soft, slurred, or slow. Speaking long sentences is tiring.

6. Swallowing problems. Food or liquids “go down the wrong way,” causing choking, coughing, or weight loss.

7. Breathing weakness. Later, the diaphragm and chest muscles weaken, causing shortness of breath and poor sleep.

8. Slowness (bradykinesia). Movements are small and slow; daily tasks take longer (bodig/parkinsonism).

9. Stiffness and rigidity. Muscles feel tight; arms do not swing during walking.

10. Postural instability and falls. Balance worsens; turning and getting up are unsafe.

11. Masked face and quiet voice. Facial expression and voice volume drop (parkinsonian features).

12. Thinking and memory problems. Trouble with planning, attention, multitasking, and new learning; family may notice personality or behavior change.

13. Apathy or mood changes. Less motivation, withdrawal, depression, or irritability may occur.

14. Sleep problems. Fragmented sleep, acting out dreams, or daytime sleepiness can appear.

15. Fluctuating picture over time. One person may start with parkinsonism, then develop weakness; another may begin with memory change. This evolution is typical of ALS/PDC. MedLink+1

---

Diagnostic tests

A) Physical exam (tests your clinician performs at the bedside)

1. Full neurological exam. Checks strength, tone, reflexes, sensation, coordination, and gait to look for the mix of upper/lower motor neuron signs and parkinsonism typical of ALS/PDC.

2. Cranial nerve and bulbar function exam. Evaluates speech clarity, swallowing, tongue movement, and gag reflex to detect bulbar weakness.

3. Gait and posture assessment. Observes walking speed, step size, turning, arm swing, posture, and start hesitation to identify parkinsonian gait and instability.

4. Cognitive screening (e.g., MoCA). A short test of memory, attention, and planning to pick up early dementia features.

5. Eye-movement exam. Looks for slowed vertical saccades or supranuclear gaze issues sometimes seen in bodig/PSP-like presentations. E-JMD

B) Manual/bedside functional tests ( quick performance tasks)

6. Finger tapping and hand open-close. Measures bradykinesia (slowness and decrement) seen in parkinsonism.

7. Rapid alternating movements (RAM). Tests coordination and speed; reduced amplitude suggests parkinsonism.

8. Pull test. A gentle backward tug checks automatic balance responses; easily falling backward signals postural instability.

9. Timed Up-and-Go (TUG). Times standing up, walking, turning, and sitting to quantify mobility and fall risk.

10. Swallow screen (bedside). Small sips and texture trials observe cough/choke risk; may lead to formal speech-language evaluation.

C) Laboratory and pathology ( ways to rule out mimics and understand tissue changes)

11. Routine blood panels. CBC, electrolytes, liver/kidney, thyroid, vitamin B12, folate, and copper help exclude treatable conditions that can resemble ALS/PDC (e.g., B12 deficiency).

12. Infection screens when indicated. Tests for HIV, syphilis, HTLV-1, etc., if clinical clues exist, to rule out secondary causes of parkinsonism/dementia/neuropathy.

13. Autoimmune/metabolic checks. ESR/CRP, autoimmune panels, and heavy-metal testing when history suggests an alternative cause.

14. Genetic testing (selective). Sometimes used to exclude common ALS or dementia genes in atypical cases; there is no single known ALS/PDC gene. JAMA Network

15. Neuropathology (post-mortem). Characteristic findings include widespread tau pathology and, in newer studies, Aβ and occasional TDP-43 changes—informative for science, not used for living diagnosis. PMC

D) Electrodiagnostic (tests of nerve and muscle function)

16. EMG (electromyography). Detects active and chronic denervation/reinnervation in muscles, supporting motor-neuron involvement typical of the lytico (ALS-like) component. (EMG patterns in ALS/PDC are described similarly to ALS.) MedLink

17. Nerve conduction studies. Usually near normal in ALS but help rule out peripheral neuropathy or other nerve diseases.

18. EEG (if seizures or unclear spells). Mostly normal in parkinsonism/ALS, but may aid in differential diagnosis when cognitive changes fluctuate.

E) Imaging ( tests that look at brain/spinal structures and function)

19. Brain MRI. May show cortical or subcortical atrophy; in some bodig cases, a “hummingbird sign” (midbrain atrophy) similar to PSP has been reported. MRI also rules out strokes, tumors, or normal-pressure hydrocephalus. E-JMD

20. Functional imaging (e.g., FDG-PET or DaTscan). PET can show reduced metabolism in frontal/temporal regions in some ALS/PDC cases; DaTscan may show dopaminergic loss in parkinsonism. These help characterize the pattern when MRI is non-specific. JAMA Network

Non-Pharmacological Treatments (Therapies & Others)

(Each includes description, purpose, and mechanism in plain English.)

1. Multidisciplinary clinic care.
   Description: Regular visits with a team (neurologist, PT, OT, SLP, respiratory therapist, dietitian, social worker).
   Purpose: Coordinate whole-person care, spot problems early, and plan ahead.
   Mechanism: Team-based assessment reduces complications (falls, malnutrition, aspiration) and aligns treatments with the patient’s goals.

2. Physical therapy (PT).
   Description: Gentle strength, flexibility, balance, and gait training; energy-conserving pacing.
   Purpose: Preserve mobility, reduce falls, and relieve stiffness.
   Mechanism: Repeated, safe movement maintains muscle length and joint range, improves balance strategies, and reduces spasticity triggers.

3. Occupational therapy (OT).
   Description: Training for dressing, bathing, writing, phone use; home/work adaptations and equipment.
   Purpose: Keep independence and safety in daily tasks.
   Mechanism: Task-specific practice + assistive devices (grab bars, raised seats, reachers) lower physical demands and injury risk.

4. Speech-language therapy (SLP).
   Description: Voice/speech strategies, swallow techniques, diet texture advice, and communication planning.
   Purpose: Make speech clearer, eating safer, and communication reliable.
   Mechanism: Compensatory techniques (posture, pacing, thickened liquids) protect airway; voice banking/AAC preserves communication.

5. Respiratory therapy + Noninvasive Ventilation (NIV).
   Description: Breathing exercises, cough assist devices, and NIV (BiPAP) when needed.
   Purpose: Support breathing, improve sleep/energy, and extend life.
   Mechanism: NIV offloads weak respiratory muscles and improves gas exchange; evidence shows NIV prolongs survival in ALS. PMC+1

6. Nutrition therapy.
   Description: High-calorie, high-protein meal plans; texture modification; hydration tips.
   Purpose: Prevent weight loss and reduce choking risk.
   Mechanism: Adequate calories slow malnutrition; safer textures lower aspiration.

7. Swallow safety training.
   Description: Small bites, slow pace, chin-tuck or head-turn maneuvers; supervised meals.
   Purpose: Reduce choking and pneumonia.
   Mechanism: Postural and pacing strategies protect the airway and coordinate swallow.

8. Cognitive and behavioral support.
   Description: Memory aids, routines, caregiver education, and counseling.
   Purpose: Preserve function and reduce distress from thinking or behavior changes.
   Mechanism: External memory supports and structured days lower cognitive load and agitation.

9. Exercise: low-to-moderate intensity.
   Description: Gentle aerobic activity (walking, cycling), light resistance bands, stretching.
   Purpose: Maintain endurance, mood, and joint motion without over-fatigue.
   Mechanism: Controlled exercise improves mitochondrial efficiency and reduces deconditioning.

10. Fall-prevention program.
    Description: Home safety review (lighting, rugs), footwear, canes/walkers, caregiver spotting.
    Purpose: Prevent injuries and hospitalizations.
    Mechanism: Environmental and equipment changes lower center-of-mass risks.

11. Assistive mobility devices.
    Description: Canes, walkers, wheelchairs, transfer boards, bathroom equipment.
    Purpose: Improve safe movement and reduce caregiver strain.
    Mechanism: Mechanical leverage replaces lost muscle power.

12. Augmentative & Alternative Communication (AAC).
    Description: From picture boards and text-to-speech apps to eye-gaze computers.
    Purpose: Keep reliable communication as speech weakens.
    Mechanism: Converts minimal movement or gaze into speech output.

13. Pressure-injury prevention.
    Description: Cushions, memory-foam mattresses, repositioning schedules, skin checks.
    Purpose: Avoid bedsores and infections.
    Mechanism: Reduces pressure/time on bony areas and moisture.

14. Sleep hygiene and fatigue management.
    Description: Regular sleep schedule, cool/dark room, caffeine timing, daytime energy budgeting.
    Purpose: Improve sleep quality and daytime alertness.
    Mechanism: Supports circadian rhythm and reduces “energy crashes.”

15. Mind-body therapy (relaxation, mindfulness).
    Description: Breathing exercises, guided imagery, meditation, prayer if desired.
    Purpose: Ease anxiety, dyspnea awareness, and caregiver stress.
    Mechanism: Lowers sympathetic arousal and improves coping.

16. Pain and spasticity self-care.
    Description: Heat, gentle massage, stretching splints, positioning.
    Purpose: Reduce muscle tightness and joint pain.
    Mechanism: Muscle temperature and length changes quiet reflex over-activity.

17. Bowel and bladder routines.
    Description: Timed toileting, fiber, fluids, stool softeners if advised.
    Purpose: Prevent constipation and incontinence-related skin issues.
    Mechanism: Regular schedules and soft stools reduce straining and accidents.

18. Education & advance-care planning.
    Description: Plain-language teaching about the disease course and options (NIV, PEG, tracheostomy, comfort-focused care).
    Purpose: Informed, values-based choices.
    Mechanism: Early discussion avoids crises and honors preferences.

19. Caregiver training and respite.
    Description: Safe transfers, feeding support, device use, and breaks for caregivers.
    Purpose: Reduce injuries and burnout.
    Mechanism: Skills + rest keep home care sustainable.

20. Palliative care (alongside all care).
    Description: Symptom relief, decision support, and psychosocial care from the start.
    Purpose: Improve quality of life at every stage.
    Mechanism: Structured attention to comfort, goals, and communication.

---

Drug Treatments

Important safety note: Doses are typical adult starting ranges; individual dosing must be set by your clinician based on age, weight, kidneys/liver, other drugs, and goals. Some drugs below treat ALS-type features, others treat parkinsonism, others treat dementia/behavior, and others relieve symptoms (drooling, cramps, spasticity). Only a few have disease-modifying evidence in ALS, and none is proven to cure Guam disease.

1. Riluzole (ALS disease-modifier; glutamate modulator).
   Dose/time: 50 mg by mouth twice daily before meals.
   Purpose: Modestly prolongs survival in ALS-type motor neuron disease.
   Mechanism: Reduces glutamate-mediated excitotoxic injury to motor neurons.
   Side-effects: Nausea, elevated liver enzymes; rare liver injury—monitor LFTs. Medscape

2. Edaravone (Radicava) (ALS disease-modifier; free-radical scavenger).
   Dose/time: IV 60 mg daily for 14 days, then 10 of 14 days each month; an oral form exists in some regions.
   Purpose: Slows functional decline in selected ALS patients.
   Mechanism: Antioxidant; reduces oxidative stress in neurons.
   Side-effects: Bruising, gait issues, headache, infusion reactions; sulfa allergy caution. PMC+1

3. Levodopa/carbidopa (dopamine replacement for parkinsonism).
   Dose/time: Often start 25/100 mg three times daily; adjust to response.
   Purpose: Improves slowness/rigidity in some with parkinsonism-dominant features.
   Mechanism: Restores brain dopamine.
   Side-effects: Nausea, low blood pressure, hallucinations, dyskinesias (later).

4. Rasagiline (MAO-B inhibitor).
   Dose/time: 0.5–1 mg daily.
   Purpose: Mild symptomatic benefit in parkinsonism; may smooth “off” time.
   Mechanism: Blocks dopamine breakdown.
   Side-effects: Headache, insomnia; serotonin syndrome risk with certain antidepressants.

5. Selegiline (MAO-B inhibitor).
   Dose/time: 5 mg twice daily (or ODT formulations).
   Purpose/mechanism: As above (dopamine preservation).
   Side-effects: Insomnia, jitteriness; drug interactions.

6. Safinamide (MAO-B inhibitor, plus antiglutamate action).
   Dose/time: 50–100 mg daily.
   Purpose: Add-on to levodopa to improve “off” time.
   Side-effects: Dyskinesia, hypertension, insomnia.

7. Pramipexole (dopamine agonist).
   Dose/time: Start 0.125 mg TID and titrate.
   Purpose: Parkinsonism symptom relief; caution in older adults with dementia.
   Mechanism: Direct dopamine receptor stimulation.
   Side-effects: Sleepiness, swelling, impulse-control disorders, hallucinations.

8. Ropinirole (dopamine agonist).
   Dose/time: Start 0.25 mg TID or extended-release once daily; titrate.
   Purpose/mechanism/side-effects: Similar to pramipexole.

9. Entacapone (COMT inhibitor).
   Dose/time: 200 mg with each levodopa dose (max 8/day).
   Purpose: Prolongs levodopa effect.
   Mechanism: Blocks levodopa breakdown in body.
   Side-effects: Diarrhea, orange urine, dyskinesias.

10. Amantadine (glutamatergic/antiviral agent).
    Dose/time: 100 mg 1–2× daily.
    Purpose: Helps levodopa-induced dyskinesia and sometimes gait freezing.
    Side-effects: Leg swelling, livedo reticularis, confusion.

11. Rivastigmine (cholinesterase inhibitor; caps or patch).
    Dose/time: 1.5 mg BID up to 6 mg BID or 4.6–13.3 mg/24 h patch.
    Purpose: Improves cognition/behavior in Parkinson’s disease dementia profile.
    Mechanism: Boosts acetylcholine signaling.
    Side-effects: Nausea, weight loss, dizziness.

12. Donepezil (cholinesterase inhibitor).
    Dose/time: 5–10 mg nightly.
    Purpose: Cognitive/behavioral symptoms.
    Side-effects: GI upset, sleep disturbance, bradycardia.

13. Memantine (NMDA receptor antagonist).
    Dose/time: 10 mg BID (titrated).
    Purpose: Attention/behavior support in moderate-severe dementia.
    Side-effects: Dizziness, headache, constipation.

14. Baclofen (oral antispastic).
    Dose/time: 5–10 mg TID; titrate to effect.
    Purpose: Reduces spasticity and cramps.
    Mechanism: GABA-B receptor agonist reduces motor neuron excitability.
    Side-effects: Sedation, weakness; taper slowly to avoid withdrawal. Palliative Care Network of Wisconsin

15. Tizanidine (oral antispastic).
    Dose/time: 2–4 mg up to 24 mg/day divided.
    Purpose/mechanism: Alpha-2 agonist reduces spasticity.
    Side-effects: Sleepiness, dry mouth, low blood pressure; liver enzyme checks. Palliative Care Network of Wisconsin

16. Dextromethorphan-quinidine (for pseudobulbar affect).
    Dose/time: 20/10 mg capsule twice daily.
    Purpose: Reduces uncontrolled laughing/crying.
    Mechanism: NMDA/sigma-1 modulation + metabolism boost via quinidine.
    Side-effects: Dizziness, diarrhea; QT prolongation risk.

17. Glycopyrrolate (for drooling).
    Dose/time: 0.5–1 mg 2–3× daily.
    Purpose: Dry secretions to reduce aspiration risk.
    Mechanism: Anticholinergic.
    Side-effects: Dry mouth, constipation, blurred vision.

18. Atropine 1% drops (sublingual, off-label) for sialorrhea.
    Dose/time: 1–2 drops under tongue up to TID as instructed.
    Purpose/mechanism: Anticholinergic to reduce drool.
    Side-effects: Dry mouth, confusion (caution in elderly).

19. Quetiapine (for distressing hallucinations/agitation).
    Dose/time: 12.5–25 mg nightly up, very gradual titration.
    Purpose: Calms behavior with lower motor side-effect risk.
    Side-effects: Sleepiness, orthostasis, metabolic changes.

20. Mexiletine (for painful cramps, select cases).
    Dose/time: Often 150 mg BID; specialist-guided.
    Purpose: Lessens muscle cramp pain.
    Mechanism: Sodium channel blocker.
    Side-effects: Nausea, tremor, arrhythmia risk—cardiac history required. Palliative Care Network of Wisconsin

Two key regulatory updates to know (context):

• AMX0035 (Relyvrio): voluntarily withdrawn from U.S./Canada in 2024 after a negative Phase 3; FDA approval withdrawn in 2025. Not recommended. Amylyx+2Federal Register Public Inspection+2

• Tofersen (Qalsody): FDA-approved only for SOD1-mutation ALS, a small subset; not a general Guam disease therapy. U.S. Food and Drug Administration+1

---

Dietary “Molecular” Supplements

Caution: No supplement has proven to cure ALS-PDC. Some have limited or negative ALS trial data. Always discuss with your clinician to avoid interactions (especially with heart, liver, kidney, or blood-thinner issues).

1. Omega-3s (ALA/EPA/DHA).
   Dose: Commonly 1–2 g/day combined EPA+DHA or dietary oily fish 2–3×/week.
   Function: Anti-inflammatory, membrane support.
   Mechanism/Evidence: Higher ALA levels linked to slower ALS progression in observational studies; RCT proof is lacking; high-dose fish oil may raise AFib risk in some. Food sources preferred. Harvard Chan School of Public Health+2American Academy of Neurology+2

2. Vitamin D3.
   Dose: Individualized to reach 25-OH vitamin D sufficiency (often 800–2000 IU/day; lab-guided).
   Function: Neuroimmune modulation; bone health.
   Mechanism/Evidence: Low levels correlate with worse outcomes in some ALS cohorts; causality unproven. SpringerLink+1

3. Vitamin B12 (methylcobalamin).
   Dose: Diet-based or oral 1 mg/day if deficient; high-dose injections are specialist decisions.
   Function: Myelin and nerve metabolism.
   Evidence: Treat deficiency; no clear ALS-PDC disease-modifying effect.

4. Folate (B9).
   Dose: 400–800 mcg/day if low; higher only under medical guidance.
   Function: One-carbon metabolism for neurons.
   Evidence: Correct deficiency; no disease-modifying proof.

5. Coenzyme Q10.
   Dose: Trials used up to 2700 mg/day; ALS Phase II showed futility—not recommended for disease modification.
   Function/Mechanism: Mitochondrial electron transport; antioxidant.
   Evidence: Negative/insufficient in ALS. PMC+1

6. Creatine.
   Dose: 5–10 g/day in trials.
   Function: Energy buffer for muscle.
   Evidence: ALS trials show no benefit on survival or function. Cochrane+1

7. Curcumin (turmeric extract).
   Dose: 500–1000 mg/day standardized curcuminoids with piperine (variable).
   Function: Anti-inflammatory; antioxidant.
   Evidence: Preclinical/adjunct only; no ALS-PDC proof.

8. Green tea EGCG.
   Dose: 200–400 mg/day EGCG or brewed tea.
   Function: Antioxidant; anti-aggregation.
   Evidence: Observational/experimental; clinical benefit unproven.

9. Melatonin.
   Dose: 1–5 mg at night.
   Function: Sleep onset and antioxidant effects.
   Evidence: Helps insomnia; disease modification unproven.

10. Magnesium (if low).
    Dose: 200–400 mg/day elemental (glycinate/citrate).
    Function: Muscle cramps and sleep support.
    Evidence: Symptom control only; watch diarrhea and kidneys.

---

Immunity-Booster / Regenerative / Stem-Cell Drugs

There are no approved regenerative drugs for Guam disease. The items below are experimental or for narrow subgroups. They should only be used in clinical trials.

1. NurOwn® (debamestrocel; MSC-NTF cells).
   Dose: Intrathecal cell infusions on trial schedules.
   Function/mechanism: Mesenchymal cells conditioned to release neurotrophic factors.
   Evidence status: Mixed/negative regulatory reviews; new Phase 3b study cleared in 2025. Not approved. AP News+1

2. Tofersen (Qalsody®) for SOD1-ALS only.
   Dose: Intrathecal loading then monthly maintenance.
   Function: Antisense oligo lowers SOD1 protein.
   Evidence: FDA accelerated approval based on NfL reduction; not applicable to typical Guam disease. U.S. Food and Drug Administration

3. Other antisense/gene therapies (various targets).
   Dose: Trial-specific.
   Function: Silence or correct disease-linked genes.
   Evidence: Investigational; relevance to ALS-PDC uncertain.

4. Intrathecal baclofen pump (ITB) — device therapy.
   Dose: Programmable intrathecal infusion.
   Function: Potent spasticity relief when oral therapy fails.
   Evidence: Can reduce spasticity/pain in selected ALS patients; surgical risks. PubMed+1

5. Neurotrophic/growth factor approaches (e.g., IGF-1) .
   Function: Support neuron survival.
   Evidence: Past trials disappointing; research continues.

6. Cell-based/biomaterial scaffolds.
   Function: Replace/support damaged neural circuits.
   Evidence: Preclinical/early clinical only.

---

Surgeries/Procedures

1. PEG feeding tube (Percutaneous Endoscopic Gastrostomy).
   What: A soft tube is placed through the abdomen into the stomach.
   Why: Maintains nutrition/hydration when swallowing is unsafe; associated with longer survival when used appropriately in ALS. American Academy of Neurology+1

2. Noninvasive ventilation (NIV) setup and titration (procedure-like care).
   What: Mask-based breathing support (BiPAP) at home.
   Why: Improves sleep, energy, and extends life in ALS; used similarly in ALS-PDC with respiratory weakness. PMC

3. Tracheostomy with invasive ventilation (select cases).
   What: Surgical airway and ventilator support.
   Why: For severe respiratory failure when long-term full-time support is desired; requires intensive caregiving.

4. Intrathecal baclofen pump implantation (see above).
   What: Programmable pump under the skin infusing baclofen into spinal fluid.
   Why: Treats severe spasticity unresponsive to pills; may improve comfort and care. PubMed

5. Botulinum toxin injections for sialorrhea (procedure).
   What: Targeted salivary gland injections.
   Why: Reduces drooling and aspiration risk when pills are inadequate.

Note: Deep brain stimulation (DBS) helps some Parkinson’s disease patients but is generally not useful when dementia is present or in atypical parkinsonism; Guam PDC often has dementia/atypical features—so DBS is usually not appropriate.

---

Ways to Prevent or Lower Risk

1. Avoid cycad products (seeds, flour) and other improperly detoxified traditional sources. PubMed

2. Do not consume wild fruit bats or other animals that may biomagnify plant toxins. The New Yorker

3. Use safe water; avoid blooms with cyanobacteria (algae) when possible. PMC

4. Eat a varied modern diet rich in vegetables, fruits, whole grains, and safe protein.

5. Maintain vitamin sufficiency (especially D and B12) under medical advice.

6. Exercise regularly at a gentle to moderate level.

7. Use protective gear and prevent head injuries.

8. Limit neurotoxin exposures at work/home (solvents, pesticides) using PPE.

9. Manage cardiovascular risk (BP, diabetes, cholesterol) for brain health.

10. Seek early care for new weakness, falls, or speech/swallow changes.

---

When to See a Doctor

• New muscle weakness, shrinking muscles, frequent cramps/twitching.

• Shuffling gait, stiffness, tremor, or repeated falls.

• Speech or swallowing trouble, coughing or choking during meals.

• Breathing changes, poor sleep with morning headaches, or daytime sleepiness.

• Memory/behavior changes that affect daily life.

• Any rapid decline, unintended weight loss, or frequent chest infections.

• If you have a family history of ALS/PDC-like illness or lived where traditional cycad use was common and have symptoms now.

---

What to Eat and What to Avoid

1. Choose soft, moist, high-calorie meals if swallowing is hard; add healthy oils, nut butters, avocado.

2. Protein at each meal (eggs, fish, poultry, tofu, dairy) to maintain muscle.

3. Plenty of fluids and fiber for bowel regularity.

4. Omega-3–rich foods (oily fish, flaxseed, walnuts) rather than high-dose supplements unless advised. Harvard Chan School of Public Health

5. Vitamin D–rich foods (fortified dairy/alternatives, safe sun, or supplement if prescribed). Oxford Academic

6. Avoid cycad products or any unverified traditional “flours.” PubMed

7. Limit alcohol (worsens falls and cognition).

8. Avoid very dry, crumbly foods if you cough with eating; use sauces and gravies.

9. Small, frequent meals if fatigue is high.

10. If weight loss continues, discuss PEG feeding early. American Academy of Neurology

---

Frequently Asked Questions

1. Is Guam disease the same as ALS?
   Not exactly. It mixes ALS-like weakness with parkinsonism and dementia in varying amounts. PubMed

2. Is it still common?
   No. Rates peaked in the 1950s–60s and then declined as traditional exposures faded. Oxford Academic

3. What likely caused the old epidemic?
   Probable environmental toxins from cycad seeds and possibly food-chain biomagnification (e.g., fruit bats) plus personal susceptibility. PubMed+1

4. Can a blood test prove it?
   No single test. Diagnosis uses history, exam, EMG, imaging, and exclusion of mimics; pathology shows tau-related changes. PubMed

5. Is there a cure?
   No cure yet. Care aims to slow decline and prevent complications.

6. Which medicines can slow it?
   From ALS care: riluzole and edaravone offer modest benefits for motor neuron decline; NIV and PEG also improve survival and quality in ALS-type disease. Medscape+2PMC+2

7. Is AMX0035 (Relyvrio) still used?
   No. It was withdrawn in 2024–2025 after a negative trial and FDA withdrawal of approval. Amylyx+1

8. What about tofersen?
   Approved only for SOD1-mutation ALS (a small subset). Not a standard treatment for Guam disease. U.S. Food and Drug Administration

9. Do supplements help?
   Food-first is best. Omega-3s have observational signals; creatine and CoQ10 did not help in ALS trials. Always check interactions. Cochrane+1

10. Can therapy really help?
    Yes. PT/OT/SLP, respiratory therapy, nutrition, and palliative care reduce complications and maintain quality of life.

11. Will I need breathing support?
    Possibly. NIV can improve sleep/energy and extend life when breathing weakens. PMC

12. Will I need a feeding tube?
    If swallowing becomes unsafe or weight drops. PEG can stabilize nutrition and extend survival. American Academy of Neurology

13. Is DBS surgery helpful?
    Usually no when dementia or atypical parkinsonism is present; Guam PDC often includes those features.

14. Can children get it?
    It mainly affects adults.

15. How can families prepare?
    Learn about the condition, plan for assistive devices, consider advance-care plans early, and use support groups and respite.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.